Day One Biopharmaceuticals (DAWN) Competitors $6.65 -0.06 (-0.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.64 -0.01 (-0.08%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. CRNX, IMVT, ALVO, MOR, OGN, NAMS, RXRX, GMTX, RARE, and MIRMShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Alvotech (ALVO), MorphoSys (MOR), Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors Crinetics Pharmaceuticals Immunovant Alvotech MorphoSys Organon & Co. NewAmsterdam Pharma Recursion Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Mirum Pharmaceuticals Crinetics Pharmaceuticals (NASDAQ:CRNX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Do institutionals & insiders believe in CRNX or DAWN? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, CRNX or DAWN? Crinetics Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500. Do analysts recommend CRNX or DAWN? Crinetics Pharmaceuticals presently has a consensus target price of $69.50, indicating a potential upside of 149.64%. Day One Biopharmaceuticals has a consensus target price of $29.00, indicating a potential upside of 336.09%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is CRNX or DAWN more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. Day One Biopharmaceuticals' return on equity of -14.98% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Day One Biopharmaceuticals -42.66%-14.98%-13.04% Does the media prefer CRNX or DAWN? In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 4 mentions for Crinetics Pharmaceuticals and 0 mentions for Day One Biopharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.88 beat Day One Biopharmaceuticals' score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Crinetics Pharmaceuticals Positive Day One Biopharmaceuticals Neutral Which has preferable earnings and valuation, CRNX or DAWN? Day One Biopharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,506.40-$298.41M-$3.82-7.29Day One Biopharmaceuticals$131.16M5.14-$95.50M-$0.71-9.37 SummaryDay One Biopharmaceuticals beats Crinetics Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$680.14M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-9.3717.7428.8623.83Price / Sales5.14178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book1.338.508.275.54Net Income-$95.50M-$55.06M$3.25B$259.28M7 Day Performance-8.02%-3.99%-3.73%-4.68%1 Month Performance-1.19%9.58%4.29%4.36%1 Year Performance-52.23%6.70%25.87%17.89% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.2526 of 5 stars$6.65-0.9%$29.00+336.1%-53.1%$680.14M$131.16M-9.3760Upcoming EarningsCRNXCrinetics Pharmaceuticals3.3272 of 5 stars$30.30-2.2%$69.50+129.4%-46.5%$2.90B$760K-7.93210News CoveragePositive NewsUpcoming EarningsIMVTImmunovant1.6664 of 5 stars$16.76-1.1%$36.40+117.2%-45.6%$2.90BN/A-6.12120Upcoming EarningsALVOAlvotech3.3884 of 5 stars$9.81+2.1%$14.00+42.7%-24.0%$2.90B$491.98M26.511,032Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.8732 of 5 stars$9.96-2.4%$18.00+80.7%-54.9%$2.65B$6.40B3.464,000Upcoming EarningsNAMSNewAmsterdam Pharma3.3287 of 5 stars$23.42-0.8%$41.30+76.3%+23.4%$2.65B$45.56M-12.464Positive NewsUpcoming EarningsRXRXRecursion Pharmaceuticals1.5288 of 5 stars$6.31-2.8%$7.00+10.9%-22.6%$2.64B$58.84M-3.56400Upcoming EarningsGap DownGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+38.5%$2.63BN/A-60.6130RAREUltragenyx Pharmaceutical4.4832 of 5 stars$27.61+1.0%$82.57+199.1%-35.6%$2.58B$560.23M-4.701,294Upcoming EarningsAnalyst RevisionMIRMMirum Pharmaceuticals3.7255 of 5 stars$51.49-0.7%$65.50+27.2%+29.6%$2.57B$336.89M-31.98140News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors Immunovant Competitors Alvotech Competitors MorphoSys Competitors Organon & Co. Competitors NewAmsterdam Pharma Competitors Recursion Pharmaceuticals Competitors Gemini Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
